Notice of Intent to Sole Source- Investigative Services Houston Police Deparment
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Food and Drug Administration (FDA) has issued a Notice of Intent to Sole Source for Investigative Services to the Houston Police Department. This action is authorized under 10 USC 2304 (c)(5). This notice is not a solicitation for competitive proposals, but other firms may express interest and capability.
Scope of Work
The requirement is for individual contracts covering investigative work. The services will support the FDA's mission, with the place of performance located in Houston, TX.
Contract & Timeline
- Type: Notice of Intent to Sole Source (Special Notice)
- Intended Awardee: Houston Police Department
- Period of Performance: 12 months from the date of award
- NAICS Code: 922120 (Police Protection)
- Product Service Code: R418 (Legal Services)
- Authority: 10 USC 2304 (c)(5) - authorized by statute
- Set-Aside: None (Sole Source)
- Published: June 21, 2026
- Notice Close Date: June 27, 2026, at 10:00 AM EST
Submission & Evaluation
This is not a request for competitive proposals. However, any other firms desiring consideration must fully identify their interest and capability to provide these services or submit a proposal within 7 days of the notice publication. Responses should be sent via email to Nina.Montgomery@fda.hhs.gov. A determination by the government not to compete the proposed contract based on responses is solely at the Government's discretion.
Contact Information
Primary Contact: Nina Montgomery (nina.montgomery@fda.hhs.gov, 240-402-8086)